Table 3 Treatment exposure (adjuvant phase)

From: Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial

Exposure

CP alone (n = 30)

CP + pembrolizumab (n = 61)

Median no. of cycles (range)

Carboplatin

3 (0–6)

3 (0–5)

Paclitaxel

3 (0–6)

3 (0–5)

Pembrolizumab

NA

15 (0–24)

Bevacizumab

14.5 (0–22)

15 (0–24)

Early discontinuation, n (%)a

Carboplatin

3 (10)

8 (13)

 Progression

2 (7)

4 (7)

 AE

1 (3)

1 (2)

 Other

0

3 (5)b

Paclitaxel

6 (20)

11 (18)

 Progression

3 (10)

4 (7)

 AE

3 (10)

4 (7)

 Other

0

3 (5)b

Pembrolizumab

NA

40 (66)

 Progression

–

24 (39)

 Toxicity

–

14 (23)c

 Other

–

2 (3)d

Bevacizumab

21 (70)

41 (67)

 Progression

15 (50)

23 (38)

 Toxicity

4 (13)

10 (16)

 Other

2 (7)e

8 (11)f

  1. AE adverse event, CP carboplatin + paclitaxel, HIPEC hyperthermic intraperitoneal chemotherapy, IDS interval debulking surgery, NA not applicable.
  2. aBefore planned end of treatment per protocol.
  3. bDeath (n = 1), HIPEC during IDS (n = 1), investigator decision (n = 1).
  4. cOne case each of grade 2 colitis, grade 3 acute renal failure, grade 3 dilated cardiomyopathy, grade 3 arthralgia, grade 2 hypothyroidism, grade 1 salivary hyposecretion, grade 3 autoimmune hepatitis, grade 3 cytolysis, grade 4 sepsis, grade 1 hypereosinophilia, grade 2 pancolitis, grade 4 left ventricular ejection fraction decreased, grade 2 hepatic cytolysis, grade 2 cholangitis.
  5. dDeath (n = 1), HIPEC during IDS (n = 1).
  6. eBreast cancer (n = 1), missing (n = 1).
  7. fNo bevacizumab administered (n = 5), patient died before adjuvant therapy (n = 1), patient decision (n = 1), missing (n = 1).
Back to article page